HLA tetramer-based artificial antigen-presenting cells efficiently stimulate CTLs specific for malignant glioma

Clinical Cancer Research

Volumn 13, Issue 24, 2007, Pages 7329-7334

  Jiang, Xiaobing ^a,d   Lu, Xiaoling ^b   Liu, Ruen ^c   Zhang, Fangcheng ^a   Zhao, Hongyang ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b FUDAN UNIVERSITY   (China)

^c CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^d HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD83 ANTIGEN; GAMMA INTERFERON; HLA A2 ANTIGEN; HLA ANTIBODY; INTERLEUKIN 13 RECEPTOR ALPHA2; INTERLEUKIN 13 RECEPTOR ALPHA2[345-354]; MONOCLONAL ANTIBODY CD28; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTING CELL; ARTICLE; CANCER CELL CULTURE; COMPLEX FORMATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; GLIOBLASTOMA; HLA SYSTEM; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOREACTIVITY; LYMPHOCYTE ACTIVATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; STAINING;

ANTIGEN-PRESENTING CELLS; ANTIGENS, CD; ANTIGENS, CD28; BRAIN NEOPLASMS; CELLS, CULTURED; COCULTURE TECHNIQUES; GENE EXPRESSION; GLIOMA; HLA ANTIGENS; HUMANS; IMMUNOGLOBULINS; INTERLEUKIN-13 RECEPTOR ALPHA2 SUBUNIT; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES, CYTOTOXIC;

EID: 37549030919     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1025     Document Type: Article

References (50)

1. Wen PY, Kesari S. Malignant gliomas. Curr Neurol Neurosci 2004;4:218-27.
2. Walker PR, Calzascia T, De Tribolet N, Dietrich PY. T-cell immune responses in the brain and their relevance for cerebral malignancies. Brain Res Brain Res Rev 2003;42:97-122.
3. Ashley DM, Faiola B, Nair S, Hale LP, Bigner DD, Gilbao E. Bone marrowgenerated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med 1997;186:1177-82.
4. Okada H, Tahara H, Shurin MR, et al. Bone marrow derived dendritic cells pulsed with a tumor specific peptide elicit effective anti-tumor immunity against intracranial neoplasms. Int J Cancer 1998;78:196-201.
5. Liau LM, Black KL, Prins RM, et al. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg 1999;90:1115-24.
6. Holladay FP, Heitz T, Chen YL, Chiga M, Wood GW. Successful treatment of a malignant rat glioma with cytotoxic T lymphocytes. Neurosurgery 1992;31:528-33.
7. Melief CJ, Kast WM. T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. Immunol Rev 1995;145:167-77.
8. Rammensee HG, Friede T, Stevanovic S. MHC ligands and peptide motifs: first listing. Immunogenetics 1995;41:178-228.
9. Murata T, Obiri NI, Debinski W, Puri RK. Structure of IL-13 receptor: analysis of subunit composition in cancer and immune cells. Biochem Biophys Res Commun 1997;238:90-4.
10. Mintz A, Gibo DM, Slagle-Webb B, Christensen ND, Debinski W. IL-13Rα2 is a glioma-restricted receptor for interleukin-13. Neoplasia 2002;4:388-99.
11. Husain SR, Puri RK. Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside. J Neurooncol 2003;65:37-48.
12. Okano F, Storkus WJ, Chambers WH, Pollack IF, Okada H. Identification of a novel HLA-A*0201 restricted cytotoxic T lymphocyte epitope in a human glioma associated antigen, interleukin-13 receptor 2 chain. Clin Cancer Res 2002;8:2851-55.
13. van Rensen AJ, Wauben MH, Grosfeld-Stulemeyer MC, van Eden W, Crommelin DJ. Liposomes with incorporated MHC class II/peptide complexes as antigen presenting vesicles for specific T cell activation. Pharm Res 1999;16:198-204.
14. Prakken B, Wauben M, Genini D, et al. Artificial antigen-presenting cells as a tool to exploit the immune 'synapse'. Nat Med 2000;6:1406-10.
15. Curtsinger J, Deeths MJ, Pease P, Mescher MF. Artificial cell surface constructs for studying receptor-ligand contributions to lymphocyte activation. J Immunol Methods 1997;209:47-57.
16. Tham EL, Jensen PL, Mescher MF. Activation of antigen-specific T cells by artificial cell constructs having immobilized multimeric peptide-class I complexes and recombinant B7-Fc proteins. J Immunol Methods 2001;249:111-9.
17. + T cells. Clin Immunol 2003;106:16-22.
18. Oelke M, Maus MV, Didiano D, June CH, Mackensen A, Schneck JP. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nat Med 2003;9:619-24.
19. Parker KC, Bednarek MA, Hull LK, et al. Sequence motifs important for peptide binding to the human MHC class Imolecule, HLA-A2. J Immunol 1992;149:3580-87.
20. Altman JD, Moss PA, Goulder PJ, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996;274:94-6.
21. Molldrem JJ, Lee PP, Wang C, Champlin RE, Davis MM. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res 1999;59:2675-81.
22. + T cell responses in vivo and in vitro. Proc Natl Acad Sci USA 1999;96:9781-86.
23. Qian L, Qian GX. In vivo CTL immunity can be elicited by OVA-linker-β2m fusion protein. Acta Biochim Biophys Sin 2002;34:547-52.
24. Maziarz RT, Fraser J, Srominger JL, Burakoff SJ. The human HLA-specific monoclonal antibody W6/32 recognizes a discontinuous epitope within the α2 domain of murine H-2Db. Immunogenetics1986;249:206-8.
25. Surawicz TS, Davis F, Freels S, Laws ER, Menck HR. Brain tumor survival: results from the National Cancer Data Base. J Neurooncol 1998;40:151-60.
26. Graf MR, Merchant RE. Interleukin-6 transduction of a ratT9 glioma clone results in attenuated tumorigenicity and induces glioma immunity in Fischer F344 rats. J Neurooncol 1999;45:209-18.
27. Graf MR, Prins RM, Merchant RE. IL-6 secretion by a rat T9 glioma clone induces a neutrophil-dependent antitumor response with resultant cellular, antiglioma immunity. J Immunol 2001;166:121-9.
28. Ram Z, Walbridge S, Heiss JD, Culver KW, Blaese RM, Oldfield EH. In vivo transfer of the human interleukin-2 gene: negative tumoricidal results in experimental brain tumors. J Neurosurg 1994;80:535-40.
29. Tjuvajev J, Gansbacher B, Desai R, et al. RG-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-γ. Cancer Res 1995;55:1902-10.
30. Barker CF, Billingham RE. Immunologically privileged sites. Adv Immunol 1977;25:1-54.
31. Prins RM, Liau LM. Immunology and immunotherapy in neurosurgical disease. Neurosurgery 2003;53:144-53.
32. Barba D, Saris SC, Holder C, Rosenberg SA, Oldfield EH. Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg 1989;70:175-82.
33. Merchant RE, Grant AJ, Merchant LH, Young HF. Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2. Cancer 1988;62:665-71.
34. Plautz GE, Miller DW, Barnett GH, et al. T cell adoptive immunotherapy of newly diagnosed gliomas. Clin Cancer Res 2000;6:2209-18.
35. Sankhla SK, Nadkarni JS, Bhagwati SN. Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors. J Neurooncol 1996;27:133-40.
36. Lillehei KO, Mitchell DH, Johnson SD, McCleary EL, Kruse CA. Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy. Neurosurgery 1991;28:16-23.
37. Quattrocchi KB, Miller CH, Cush S, et al. Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas. J Neurooncol 1999;45:141-57.
38. Heimberger AB, Archer GE, Crotty LE, et al. Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma. Neurosurgery 2002;50:158-64.
39. Glick RP, Lichtor T, Mogharbel A, Taylor CA, Cohen EP. Intracerebral versus subcutaneous immunization with allogeneic fibroblasts genetically engineered to secrete interleukin-2 in the treatment of central nervous system glioma and melanoma. Neurosurgery 1997;41:898-906.
40. Glick RP, Lichtor T, de Zoeten E, Deshmukh P, Cohen EP. Prolongation of survival of mice with glioma treated with semiallogeneic fibroblasts secreting interleukin-2. Neurosurgery 1999;45:867-74.
41. + cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. Proc Natl Acad Sci U S A 1996;93:10399-404.
42. + progenitor-derived dendritic cells. J Exp Med 2004;199:1503-11.
43. Hirschowitz EA, Foody T, Kryscio R, Dickson L, Sturgill J, Yannelli J. Autologous dendritic cell vaccines for non-small-cell lung cancer. J Clin Oncol 2004;22:2808-15.
44. Oelke M, Schneck JP. HLA-Ig-based artificial antigen-presenting cells: eetting the terms of engagement. Clin Immunol 2004;110:243-51.
45. Salter RD, Howell DN, Gresswell P. Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenetics 1985;21:235-46.
46. + Melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy. Clin Cancer Res 2000;6:1997-2005.
47. Salgaller ML, Lodge PA, Mclean JG, et al. Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA). Prostate 1998;35:144-51.
48. Walunas TL, Lenschow DJ, Bakker CY, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994;1:405-13.
49. + T cells and preferential enrichment for antigen specificity. Blood 2006;107:1528-36.
50. + lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell. Clin Cancer Res 2007;13:1857-67.